Results 181 to 190 of about 3,393 (249)

Cascade Valorisation of Lemon Processing Residues (Part II): Integrated Biorefinery Design, Circular Economy, and Techno-Economic Feasibility. [PDF]

Foods
Núñez-Pérez J, Burbano-García JL, Espín-Valladares R, Lara-Fiallos MV, DelaVega-Quintero JC, Cevallos-Vallejos M, Pais-Chanfrau JM.   +6 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Anti-vascular endothelial growth factor therapy in clinical practice: Real-world scenarios, limitations, and outcomes. [PDF]

Indian J Ophthalmol
Sharma D, Gupta T.
europepmc   +1 more source

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

British Journal of Clinical Pharmacology, EarlyView.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert, Carl M. J. Kirkpatrick, Rory Marriott, Siladitya Ray Chaudhuri, David Polidori, Bart Remmerie, Michelle P. McIntosh   +6 more
wiley   +1 more source

Regulated multi-growth stage deficit drip irrigation improves growth attributes, water productivity, and yield performance of maize for hybrid seed production in an arid region. [PDF]

BMC Plant Biol
Zhang Y, Xiao R, Zhao Y, Deng H, Zhang H.   +4 more
europepmc   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, EarlyView.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source

A comparative study on the cleaning efficacy of a pulsed vacuum cleaning and disinfection device on rigid endoscopic instruments in a hospital setting. [PDF]

Front Cell Infect Microbiol
Bo L, Wang X, Li J, Hu Y.
europepmc   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa, Hayato Shimazaki, Shunji Igarashi, Yoshiki Tagawa, Naoki Hisada, Hiromi Shibasaki   +5 more
wiley   +1 more source

Phytosomes against melanoma: disrupting molecular pathways with targeted phytochemical delivery. [PDF]

Discov Nano
Uniyal P, Bhardwaj N, Raina D.
europepmc   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source